Targeting Resistant ALK+ NSCLC: Primary Findings from the Pivotal Deulorlatinib Phase 2 Trial – IASLC
IASLC/LinkedIn

Targeting Resistant ALK+ NSCLC: Primary Findings from the Pivotal Deulorlatinib Phase 2 Trial – IASLC

International Association for the Study of Lung Cancer (IASLC), shared on LinkedIn:

“Deulorlatinib (TGRX-326) has reported promising activity and a favorable safety profile in ALK positive NSCLC in a phase 1 trial.

Here, the authors report the primary results of the pivotal phase 2 trial (NCT05955391) evaluating deulorlatinib in patients with ALK-positive NSCLC in whom second-generation ALK inhibitors had failed.

Read the full report.”

Article: Deulorlatinib (TGRX-326) in ALK Gene Fusion Positive NSCLC After Failure of Second-Generation Inhibitors: A Single-Arm, Multicenter, Phase 2 Trial

Authors: Jie Huang, Gang Chen, Zhehai Wang, Wenjian Jin, Yanqiu Zhao, Yongchang Zhang, Wu Zhuang, Ying Xin, Yan Wang, Jianying Zhou, Longhua Sun, Bo Jin, Guifang Zhang, Wenxiu Yao, Tienan Yi, Xiaobo Du, Fangling Ning, Jianhua Chang, Yubiao Guo, Ying Hu, Changli Wang, Weiwei Ouyang, Zhiqiang Cai, Baohui Han, Rui Meng, Zhenyu Ding, Haichuan Su, Xingya Li, Xinmin Yu, Mingwei Chen, Gaofeng Li, Yan Zhang, Jing Wang, Rui Ma, Beilei Gong, Chao Cao, Bo Wu, Chao Lei, Jingrong Cao, Yuanyuan Zhao, Ting Zhou, Shen Zhao, Yan Huang, Li Zhang, Yunpeng Yang

You can also read:

Deulorlatinib in ALK-Positive NSCLC: Can Deuteration Improve on Lorlatinib?Targeting Resistant ALK+ NSCLC: Primary Findings from the Pivotal Deulorlatinib Phase 2 Trial - IASLC